Hanson Wade Intelligence’s Post

Oligos, RNA, and Biopharma Partnering... My colleague, Phillip Leclair and I got to sit down with Advancing RNA and Michelle Raley to discuss the evolving landscape across the partnering landscape for ASOs and RNA. You can check it out here: https://lnkd.in/du6dg-gK ...Or read our key takeaways (but please do pull it up): -Oligonucleotide and RNA therapeutics are regaining industry interest post-pandemic, with partnerships increasing as these modalities mature and demonstrate commercial success (e.g., Novo Nordisk, Lilly, and several other deal-interested pharma). -Key partnering areas include RNA editing, driven by promising recent data (e.g., Wave Life Sciences that pushed most companies' stock in this space like Korro Bio, ProQR, and others), and novel delivery mechanisms aimed at expanding beyond liver targets. -The potential for AI-driven discovery in RNA therapeutics presents a new frontier for collaboration and innovation in the space. Have a look and let us know if you agree. What's your takeaways as ASOs and RNAs increasingly come back into the limelight? #genetherapy #RNA #pharma

For more than a decade, single-cell RNA sequencing, or scRNA-seq, has played a critical role in identifying the molecular mechanisms driving complex diseases and, in turn, pinpointing the specific types of cells for which a drug works. But analyzing scRNA-seq data has never been straightforward, limiting its practical utility to researchers.   To harness the full potential of human cell data to create better therapies, we need to translate scRNA-seq to the functional level by annotating de novo cell types and building cell-type references researchers can actually use. My ZS colleagues Thomas Skot Jensen, Pascal Timshel, Christina Bligaard Pedersen and Francisco Avila Cobos describe how creating a periodic table of cells can help unlock the therapeutic potential of single-cell-based approaches. https://lnkd.in/di_iUbu8 #pharma #drugdiscovery 

Reflecting on my time at the RNA Leaders Conference last week, here are my top takeaways: 1) Excellent talks and panels. The PolymerRAISE series was on another level of conference pitches. Especially loved the talks from Rabia T. K. at Serna Bio and Carter Palmer at Third Element Biosciences. Also really resonated with the corporate values reflected by execs at Johnson & Johnson and Novo Nordisk. 2) The RNA space is moving beyond the liver and CNS, where delivery was most straightforward in early days, and I’m excited to see where innovative targeting platforms take mRNA and saRNA therapeutics and vaccines, and how that effects dosing. 3) Storytelling is as important as ever in partnering in this space as in others. Platform companies need to make a compelling case for how the technology they’re using fits the indication and population they’ve chosen for their lead asset. This helps decision makers in pharma really see how a deal with you will fit into their portfolio and have impact on the market Excited to fold what I’ve learned into the work we do! 🧠 📓 #biotech #rna #therapeutics #computationalbiology #conferencereflections

Today at #ASGCT we will be sharing additional data from our team at Vesigen Therapeutics, Inc., including #targeted #delivery of #genomeeditors to a variety of cells, which we hope will enable new therapeutic strategies for diseases with unmet need. Please come by our posters, listed below, if interested in learning more: ARMMs as Non-Viral Vehicles for the Delivery of Therapeutic Payloads to Liver Sinusoidal Endothelial Cells Abstract Number: 1238 Fractionation of distinct extracellular vesicle populations by charge and density to evaluate the heterogeneity and purity of ARMMs Abstract Number: 1246 ARMMs as a Versatile and Modular Non-Viral Platform for the Functional Delivery of Genome Editors Abstract Number: 1247 Engineering ARMMs with Modular T Cell-Specific Engagers for Non-Viral Delivery of Therapeutic Payloads Abstract Number: 1248 Engineering Directed Tropism in the Non-Viral ARMMs Delivery Platform Abstract Number: 1249 #nonviral #invivo #drugdelivery #genomeediting

𝗜𝘀 𝗥𝗡𝗔 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝘁𝗵𝗲 𝗵𝗶𝗱𝗱𝗲𝗻 𝗸𝗲𝘆 𝘁𝗼 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀? Behind every RNA-based treatment, a complex folding process can either drive success or lead to failure. In our latest eBlog, we reveal how RNA’s intricate structure influences the stability of vaccines, the success of small molecule drugs, and the power of siRNA therapies. The answers could redefine how we design the next generation of RNA medicines.   Discover the science behind it all in our eBlog! https://lnkd.in/gJpw8Yza #RNAInnovation #Therapeutics #Genomics #Biotech #RNAstructure #Eclipsebio 

𝗘𝗻𝗵𝗮𝗻𝗰𝗲 𝘆𝗼𝘂𝗿 𝗺𝗥𝗡𝗔 𝗾𝘂𝗮𝗹𝗶𝘁𝘆: 𝗮𝗰𝗰𝗲𝘀𝘀 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝘄𝗵𝗶𝘁𝗲𝗽𝗮𝗽𝗲𝗿𝘀   Since March we launched 4 new whitepapers with the main focus on improving the quality of mRNA and they are still available for free download on our website. Our team of experts, with over 30 years of experience in RNA technology, has poured their expertise into these papers, 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴 𝘆𝗼𝘂 𝗳𝗿𝗲𝘀𝗵 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝗶𝗲𝘀 in:   🥼Utilizing 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 and 𝗧𝗵𝗶𝗿𝗱-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 for RNA Quality Attribute Monitoring by Anna-Marei Böhm 🥼 Why 𝗺𝘂𝗹𝘁𝗶𝗳𝗮𝗰𝗲𝘁𝗲𝗱 𝗽𝗵𝘆𝘀𝗶𝗰𝗼𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗰𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 is key to ensure the stability of your mRNA-LNP drug product by Sarah Vandenberghe 🥼Improving mRNA Quality by 𝗥𝗲𝗺𝗼𝘃𝗮𝗹 𝗼𝗳 𝗧𝗿𝘂𝗻𝗰𝗮𝘁𝗲𝗱 𝗺𝗥𝗡𝗔 𝗦𝗽𝗲𝗰𝗶𝗲𝘀 by Oligodt Purification by Mateusz Kozarski 🥼 Strengthening 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 𝗼𝗳 𝗗𝗼𝘂𝗯𝗹𝗲-𝗦𝘁𝗿𝗮𝗻𝗱𝗲𝗱 𝗥𝗡𝗔 in mRNA Manufacturing Processes by Senne Dillen   Whether you're in a start-up, early-stage, or late-stage project, our proprietary platforms can support your journey in RNA therapeutics. Dive into our latest research and discover how we can help drive your pipeline development or resolve manufacturing challenges.   Click below to download your copies now and stay ahead in the ever-evolving field of RNA therapeutics! 👉 https://lnkd.in/eyaS-f34

All RNAs fold into complex structures that regulate RNA biology and the effectiveness of RNA-targeting and RNA-based medicines. In this month's eBlog I review some of the key aspects of RNA structure and how it can affect the efficacy of RNA vaccines, small molecule drugs, and small oligonucleotide therapies.

8 weeks to go until experts working on circular, self amplifying and transfer RNAs come together in Boston for the Next Generation RNA Therapeutics Summit! See the program here: https://ter.li/row02s Addressing key challenges like sequence design, purity, stability, safety and translatability into clinical settings, this intimate meeting is your chance to hear from the leading minds of the field to gain strategic and scientific insights to fast track circular RNAs, self-amplifying RNAs and transfer RNAs into the clinic. ⏩ Navigate the intricate landscape of circular RNA production, encompassing manufacturing challenges such as yield, scalability and purity to ensure the production of exceptional circular RNA therapeutics ⏩ Foster collaboration and bolster the advancements of emerging innovations in circular, transfer and self-amplifying RNA technologies by forging connections between pharmaceutical companies, biotechs, and investors ⏩ Enhance delivery platforms for next generation RNA therapeutics and overcome delivery hurdles including stability, cellular uptake, and tissue specificity to unlock therapeutic efficacy With the early booking rate expiring this Friday, March 15, secure your early bird savings and register here: https://ter.li/ghg6s5 #circularRNA #circRNA #selfamplifyingRNA #saRNA #transferRNA #tRNA #nextgenerationRNA #RNATherapeutics #RNA #RNAVaccines

COVID-19 brought about the mRNA vaccine and a paradigm shift to a new mode of treating and preventing diseases. In this paper, the author provide a perspective on RNA technology and its applications, including examples of proposed mRNA product designs and regulatory plans to assist and encourage developers to achieve faster regulatory approval.   📝 RNA Therapeutics: A Healthcare Paradigm Shift — Sarfaraz K. Niazi.   Full text is available 👇 https://lnkd.in/dnJ9kqds   #medicine #health #research #science

🧬 Happy RNA Day! 🎉 Celebrate RNA Day with a special offer! ✨ Save 10% on TIDES Europe's Main Conference or Main Conference + Workshop Passes until Friday night. Use VIP code "RNADAY" at checkout and join us for cutting-edge insights in RNA research and therapeutics. 🎟️ https://lnkd.in/ejZ-whRu RNA-based medicines have skyrocketed in popularity, especially after the success of COVID-19 mRNA vaccines. However, the demand is outpacing current manufacturing capacities. With 21 FDA-approved RNA therapies as of April 2024, the need for innovative production methods is urgent. Traditional RNA synthesis methods are struggling, leading to bottlenecks and environmental concerns. But there's hope! Continuous manufacturing and new aqueous-based synthesis methods are set to revolutionize the industry. These innovative approaches promise lower costs, improved quality, and a smaller ecological footprint. 🌍 Let's pave the way for broader, sustainable production of RNA therapeutics! 📖 Read more about these game-changing advancements: https://lnkd.in/eQSCpYMu #TIDESEurope #RNADAY #RNA #Biotech #ContinuousManufacturing #SustainableScience #HealthcareInnovation